Abstract
Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 117-120 |
| Number of pages | 4 |
| Journal | In Vivo |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2017 |
Fingerprint
Keywords
- Concurrent Radiochemotherapy
- Local Control
- Metastases-Free Survival
- Non-Metastatic Bile Duct Cancer
- Overall Survival.
- Radiotherapy
ASJC Scopus subject areas
- Medicine(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology
Cite this
Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. / Bolm, Louisa; Kaesmann, Lukas; Bartscht, Tobias; Schild, Steven E.; Rades, Dirk.
In: In Vivo, Vol. 31, No. 1, 2017, p. 117-120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer
AU - Bolm, Louisa
AU - Kaesmann, Lukas
AU - Bartscht, Tobias
AU - Schild, Steven E.
AU - Rades, Dirk
PY - 2017
Y1 - 2017
N2 - Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.
AB - Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.
KW - Concurrent Radiochemotherapy
KW - Local Control
KW - Metastases-Free Survival
KW - Non-Metastatic Bile Duct Cancer
KW - Overall Survival.
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85015970835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015970835&partnerID=8YFLogxK
U2 - 10.21873/invivo.11033
DO - 10.21873/invivo.11033
M3 - Article
C2 - 28064229
AN - SCOPUS:85015970835
VL - 31
SP - 117
EP - 120
JO - In Vivo
JF - In Vivo
SN - 0258-851X
IS - 1
ER -